Physician profile
Max Barney
NPI 1720448590
$980.91
in general payments reported to CMS, 2019-2025
16 companies · $167 in 2025
The $167 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $447 · 2022: $84.93 · 2023: $79.00 · 2024: $203 · 2025: $167.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $449.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $449.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $412.28 | 2021-2025 | |
| Abbott Laboratories | $99.61 | 2021-2022 | |
| Astellas Pharma US INC | $91.03 | 2021-2025 | Veozah |
| Pfizer INC. | $67.94 | 2021 | |
| Lilly USA, LLC | $67.26 | 2021-2025 | Zepbound, Mounjaro |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $54.12 | 2025 | Caplyta |
| Novo Nordisk INC | $33.60 | 2021-2025 | |
| Exeltis, USA INC. | $29.41 | 2024 | Slynd |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.23 | 2021 | |
| Arbor Pharmaceuticals, INC. | $16.47 | 2021 | |
| Janssen Pharmaceuticals, INC | $15.77 | 2021 | |
| Boston Scientific Corporation | $15.24 | 2021 | |
| Novartis Pharmaceuticals Corporation | $14.30 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $12.29 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $11.69 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $11.67 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Max Barney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.